Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
New crypto investors should know key insights to thrive in the market. Equip yourself with the right information for success.
28,386 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
MISMO releases a white paper detailing how standardized fee descriptions could streamline mortgage disclosures and lo...
A rural Maine factory once central to pandemic testing is expanding its operations and product lines, highlighting a ...
Microsoft is reshaping its Xbox division with sweeping layoffs exceeding 3,000 workers, signaling a hard reset that c...
OpenAI’s Sam Altman apologized for sloppy wording in announcing a Pentagon contract, pledging a revised release to em...
DraftKings stock slides as a Senate measure targets prediction markets, while Penn Entertainment holds steady amid re...
A National Bureau of Economic Research paper shows escaping your income bracket no longer guarantees wealth, a findin...
A single metric helps explain the uneasy mood among Americans: the declining share of income going to workers as prof...
The U.S. government is on a heavy borrowing pace in fiscal 2026, with monthly borrowing around $155 billion and inter...
Interactive Brokers clients favored Nvidia after its record quarter, purchasing the stock as it pulled back from the ...
As geopolitical tensions flare and oil costs surge, recession odds jump higher. Moody's Analytics now grids a near-50...
A nationwide shift toward local, community-focused shopping is fueling independent book stores growing. New ABA data ...